An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities

Isabella Slaby, Heather S Hain, Debra Abrams, Frank D Mentch, Joseph T Glessner, Patrick M A Sleiman, Hakon Hakonarson, Isabella Slaby, Heather S Hain, Debra Abrams, Frank D Mentch, Joseph T Glessner, Patrick M A Sleiman, Hakon Hakonarson

Abstract

Background: In over half of pediatric cases, ADHD presents with comorbidities, and often, it is unclear whether the symptoms causing impairment are due to the comorbidity or the underlying ADHD. Comorbid conditions increase the likelihood for a more severe and persistent course and complicate treatment decisions. Therefore, it is highly important to establish an algorithm that identifies ADHD and comorbidities in order to improve research on ADHD using biorepository and other electronic record data.

Methods: It is feasible to accurately distinguish between ADHD in isolation from ADHD with comorbidities using an electronic algorithm designed to include other psychiatric disorders. We sought to develop an EHR phenotype algorithm to discriminate cases with ADHD in isolation from cases with ADHD with comorbidities more effectively for efficient future searches in large biorepositories. We developed a multi-source algorithm allowing for a more complete view of the patient's EHR, leveraging the biobank of the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). We mined EHRs from 2009 to 2016 using International Statistical Classification of Diseases and Related Health Problems (ICD) codes, medication history and keywords specific to ADHD, and comorbid psychiatric disorders to facilitate genotype-phenotype correlation efforts. Chart abstractions and behavioral surveys added evidence in support of the psychiatric diagnoses. Most notably, the algorithm did not exclude other psychiatric disorders, as is the case in many previous algorithms. Controls lacked psychiatric and other neurological disorders. Participants enrolled in various CAG studies at CHOP and completed a broad informed consent, including consent for prospective analyses of EHRs. We created and validated an EHR-based algorithm to classify ADHD and comorbid psychiatric status in a pediatric healthcare network to be used in future genetic analyses and discovery-based studies.

Results: In this retrospective case-control study that included data from 51,293 subjects, 5840 ADHD cases were discovered of which 46.1% had ADHD alone and 53.9% had ADHD with psychiatric comorbidities. Our primary study outcome was to examine whether the algorithm could identify and distinguish ADHD exclusive cases from ADHD comorbid cases. The results indicate ICD codes coupled with medication searches revealed the most cases. We discovered ADHD-related keywords did not increase yield. However, we found including ADHD-specific medications increased our number of cases by 21%. Positive predictive values (PPVs) were 95% for ADHD cases and 93% for controls.

Conclusion: We established a new algorithm and demonstrated the feasibility of the electronic algorithm approach to accurately diagnose ADHD and comorbid conditions, verifying the efficiency of our large biorepository for further genetic discovery-based analyses.

Trial registration: ClinicalTrials.gov, NCT02286817 . First posted on 10 November 2014.

Clinicaltrials: gov, NCT02777931 . First posted on 19 May 2016.

Clinicaltrials: gov, NCT03006367 . First posted on 30 December 2016.

Clinicaltrials: gov, NCT02895906 . First posted on 12 September 2016.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Concept overview of ADHD with comorbidities algorithm. Details for cases and controls are outlined in methods and supplementary tables
Fig. 2
Fig. 2
ADHD with all comorbidities. Number of ADHD cases in isolation and with comorbidities

References

    1. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434–442. doi: 10.1093/ije/dyt261.
    1. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212. doi: 10.1080/15374416.2017.1417860.
    1. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4). 10.1542/peds.2019-2528 published Online First: Epub Date.
    1. Hinshaw SP. Attention deficit hyperactivity disorder (ADHD): controversy, developmental mechanisms, and multiple levels of analysis. Annu Rev Clin Psychol. 2018;14:291–316. doi: 10.1146/annurev-clinpsy-050817-084917.
    1. Heidbreder R. ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis. Atten Defic Hyperact Disord. 2015;7(4):249–269. doi: 10.1007/s12402-015-0171-4.
    1. Koolwijk I, Stein DS, Chan E, Powell C, Driscoll K, Barbaresi WJ. “Complex” attention-deficit hyperactivity disorder, more norm than exception? Diagnoses and comorbidities in a developmental clinic. J Dev Behav Pediatr. 2014;35(9):591–597. doi: 10.1097/DBP.0000000000000109.
    1. Reale L, Bartoli B, Cartabia M, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443–1457. doi: 10.1007/s00787-017-1005-z.
    1. Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7(1):27–38. doi: 10.1007/s12402-014-0142-1.
    1. Connolly J, Glessner J, Elia J, Hakonarson H. ADHD & pharmacotherapy: past, present and future: a review of the changing landscape of drug therapy for attention deficit hyperactivity disorder. Ther Innov Regulat Sci. 2015;49(5):632. doi: 10.1177/2168479015599811.
    1. Connor DF. Pharmacological management of pediatric patients with comorbid attention-deficit hyperactivity disorder oppositional defiant disorder. Paediatr Drugs. 2015;17(5):361–371. doi: 10.1007/s40272-015-0143-3.
    1. Gruschow SM, Yerys BE, Power TJ, Durbin DR, Curry AE. Validation of the use of electronic health records for classification of ADHD status. J Atten Disord. 2019;23(13):1647–1655. doi: 10.1177/1087054716672337.
    1. Guevara J, Lozano P, Wickizer T, Mell L, Gephart H. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(1):71–78. doi: 10.1542/peds.108.1.71.
    1. Daley MF, Newton DA, DeBar L, et al. Accuracy of electronic health record-derived data for the identification of incident ADHD. J Atten Disord. 2017;21(5):416–425. doi: 10.1177/1087054713520616.
    1. Conway M, Berg RL, Carrell D, et al. Analyzing the heterogeneity and complexity of electronic health record oriented phenotyping algorithms. AMIA Annu Symp Proc. 2011;2011:274–283.
    1. Shivade C, Raghavan P, Fosler-Lussier E, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc. 2014;21(2):221–230. doi: 10.1136/amiajnl-2013-001935.
    1. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther. 2011;89(3):379–386. doi: 10.1038/clpt.2010.260.
    1. Gur RC, Richard J, Calkins ME, et al. Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology. 2012;26(2):251–265. doi: 10.1037/a0026712.
    1. Connolly JJ, Glessner JT, Li D, Sleiman PMA, Hakonarson H. The Center for Applied Genomics at The Children’s Hospital of Philadelphia – pediatric perspectives on genomic medicine. J Precision Med. 2020;6. .
    1. Li YR, Glessner JT, Coe BP, et al. Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. Nat Commun. 2020;11(1):255. doi: 10.1038/s41467-019-13624-1.
    1. Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016;23(6):1046–1052. doi: 10.1093/jamia/ocv202.
    1. Bush RA, Connelly CD, Perez A, Barlow H, Chiang GJ. Extracting autism spectrum disorder data from the electronic health record. Appl Clin Inform. 2017;8(3):731–741. doi: 10.4338/ACI-2017-02-RA-0029.
    1. Ingram WM, Baker AM, Bauer CR, et al. Defining major depressive disorder cohorts using the EHR: multiple phenotypes based on ICD-9 codes and medication orders. Neurol Psychiatry Brain Res. 2020;36:18–26. doi: 10.1016/j.npbr.2020.02.002.
    1. Castro VM, Minnier J, Murphy SN, et al. Validation of electronic health record phenotyping of bipolar disorder cases and controls. Am J Psychiatry. 2015;172(4):363–372. doi: 10.1176/appi.ajp.2014.14030423.
    1. Sulkes SB. Pediatrics, learning and developmental disorders, attention-deficit/hyperactivity disorder (ADD, ADHD) Whitehouse Station: Merck Sharp & Dohme Corp; 2020.
    1. Elia J. Pediatrics, Mental disorders in children and adolescents. Whitehouse Station: Merck Sharp & Dohme Corp; 2019.
    1. APA . Diagnostic and statistical manual of mental disorders: DSM-IV: fourth edition. Washington, DC: American Psychiatric Association; 1994.
    1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–948. doi: 10.1176/ajp.2007.164.6.942.
    1. MTA. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–1086. doi: 10.1001/archpsyc.56.12.1073.
    1. Biederman J, Ball SW, Monuteaux MC, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry. 2008;47(4):426–434. doi: 10.1097/CHI.0b013e31816429d3.
    1. DuPaul GJ, Gormley MJ, Laracy SD. Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil. 2013;46(1):43–51. doi: 10.1177/0022219412464351.
    1. Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51:63–75. doi: 10.1038/s41588-018-0269-7.
    1. Rovira P, Demontis D, Sánchez-Mora C, et al. Shared genetic background between children and adults with attention deficit/hyperactivity disorder. Neuropsychopharmacol. 2020;45:1617–1626. doi: 10.1038/s41386-020-0664-5.
    1. Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011;44(1):78–84. doi: 10.1038/ng.1013.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅